Journal Information
Vol. 15. Issue 1.
Pages 60-65 (January - February 2011)
Share
Share
Download PDF
More article options
Vol. 15. Issue 1.
Pages 60-65 (January - February 2011)
Brief communication
Open Access
HIV-1 drug resistance genotypic profiles in children with undetectable plasma viremia during antiretroviral therapy
Visits
2190
Daniela Souza Araújo de Angelis1, Adriana Fumie Tateno1, Ricardo Sobhie Diaz2, Regina Célia de Menezes Succi2, Claudio Sergio Pannuti1, Aida de Fátima Barbosa Gouvea2, Daisy Maria Machado1,2,
Corresponding author
dm.machado@uol.com.br

Correspondence to: Av. Dr. Enéas de Carvalho Aguiar, 470 05403-000 São Paulo, Brazil Phone: 55(11)3061-7020.
1 Laboratório de Virologia, Instituto de Medicina Tropical de São Paulo, Universidade de São Paulo, São Paulo, Brazil
2 Universidade Federal de São Paulo, São Paulo, Brazil
This item has received

Under a Creative Commons license
Article information
Abstract

Treatment of HIV-1 infection with highly active antiretroviral therapy has led to sustained viral suppression in the plasma in a large number of children. However, studies have suggested that the integrated provirus in resting CD4+ T lymphocytes could be a source of reactivatable virus and maintain drug-resistant virus. We evaluated the resistance-related mutations in children receiving antiretroviral therapy with prolonged viral suppression. Thirty-two peripheral blood mononuclear cell samples from 16 children with viral loads that had been below detection limits for at least 12 months were obtained at two different time points and the DNAs sequenced. The median CD4 cell count was 1,016 cells/ mm3 (347-2,588) and 938 cells/mm3 (440-3,038) at the first and second time points, respectively. The median follow-up time was 15 months (9-27). Six (37.5%) and seven (43.75%) of the 16 patients showed at least one NRTI-associated mutation in the first and second samples, respectively. Two out of 16 (12.5%) had an NNRTI-associated mutation at the first time point and three out of 16 (18.75%) at the second. In addition, 14 out of 16 (87.5%) had at least one PI-associated mutation at both time points. Despite plasma HIV-1 RNA suppression for at least 12 months, resistance-related mutations from previous antiretroviral failures could still be detected in archival virus. Furthermore, viral evolution occurred at the reverse transcriptase region in spite of viral suppression to levels below 400 copies/mL. Persistence of archival resistant virus may be relevant when considering future treatment options.

Keywords:
children
HIV-1
prolonged viral suppression
antiretroviral therapy
antiretroviral resistance
Full text is only aviable in PDF
References
[1.]
R. de la Rosa, E. Ruiz-Mateos, A. Rubio, et al.
Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.
J Antimicrob Chemother, 53 (2004), pp. 95-101
[2.]
F.J. Palella Jr, K.M. Delaney, A.C. Moorman, et al.
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.
N Engl J Med, 338 (1998), pp. 853-860
[3.]
A. Saitoh, K. Hsia, T. Fenton, et al.
Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children.
J Infect Dis, 185 (2002), pp. 1409-1416
[4.]
M. Hermankova, S.C. Ray, C. Ruff, et al.
HIV-1 drug resistance profiles in children and adults with viral load of < 50 copies/mL receiving combination therapy.
JAMA, 286 (2001), pp. 196-207
[5.]
J. Izopet, L. Sailler, K. Sandres, et al.
Intermittent selection pressure with zidovudine plus zalcitabine treatment reduces the emergence in vivo of zidovudine resistance HIV mutations.
J Med Virol, 57 (1999), pp. 163-168
[6.]
D. Persaud, T. Pierson, C. Ruff, et al.
A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children.
J Clin Invest, 105 (2000), pp. 995-1003
[7.]
S. Resino, B. Larru, J. Maria Bellon, et al.
Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.
BMC Infect Dis, 6 (2006), pp. 107
[8.]
A. De Rossi.
Virological and immunological response to antiretroviral therapy in HIV-1 infected children: genotypic and phenotypic assays in monitoring virological failure.
New Microbiol, 27 (2004), pp. 45-50
[9.]
E.G. Hermione Lyall.
Paediatric HIV in 2002--a treatable and preventable infection.
J Clin Virol, 25 (2002), pp. 107-119
[10.]
P.J. Gavin, R. Yogev.
The role of protease inhibitor therapy in children with HIV infection.
Paediatr Drugs, 4 (2002), pp. 581-607
[11.]
J.R. Bailey, A.R. Sedaghat, T. Kieffer, et al.
Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4 T Cells.
J Virol, 80 (2006), pp. 6441-6457
[12.]
C.T. Ruff, S.C. Ray, P. Kwon, et al.
Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.
J Virol, 76 (2002), pp. 9481-9492
[13.]
O. Lambotte, M.L. Chaix, B. Gubler, et al.
The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution.
AIDS, 18 (2004), pp. 1147-1158
[14.]
M. Zanchetta, S. Walker, N. Burighel, et al.
Long-term decay of the HIV-1 reservoir in HIV-1-infected children treated with Highly Active Antiretroviral Therapy.
J Infect Dis, 193 (2006), pp. 1718-1726
[15.]
T. Matthews, M. Salgo, M. Greenberg, et al.
Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.
Nat Rev Drug Discov, 3 (2004), pp. 215-225
[16.]
M.D. Iglesias-Ussel, C. Casado, E. Yuste, I. Olivares, C. Lopez- Galindez.
In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants.
J Gen Virol, 83 (2002), pp. 93-101
[17.]
M. Sturmer, A. Berger, W. Preiser.
HIV-1 genotyping: comparison of two commercially available assays.
Expert Rev Mol Diagn, 4 (2004), pp. 281-291
[18.]
L. Zhang, B. Ramratnam, K. Tenner-Racz, et al.
Quantifying residual HIV-1 replication in patients receiving combination anti-retroviral therapy.
N Engl J Med, 340 (1999), pp. 1605-1613
[19.]
S.E. Starr, C.V. Fletcher, A.S. Spector, et al.
Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency vírus type 1. Pediatric AIDS Clinical Trials Group 382 Team.
N Engl J Med, 341 (1999), pp. 1874-1881
[20.]
A.M. Van Rossum, P.L. Fraaij, R. de Groot.
Efficacy of highly active anti-retroviral therapy in HIV-1 infected children.
Lancet Infect Dis, 2 (2002), pp. 93-102
[21.]
J.W. Cohen Stuart, A.M. Wensing, C. Kovacs, et al.
Transient relapses (“blips”) of plasma HIV RNA levels during HAART are associated with drug resistance.
J Acquir Immune Defic Syndr, 28 (2001), pp. 105-113
[22.]
L.K. Naeger, K.A. Struble.
Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients.
[23.]
G.M. Lucas.
Anti-retroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven.
J Antimicrob Chemother, 55 (2005), pp. 413-416
[24.]
J. Ghosn, I. Pellegrin, C. Goujard, et al.
HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
Copyright © 2011. Elsevier Editora Ltda.. All rights reserved
The Brazilian Journal of Infectious Diseases
Article options
Tools